Special Issue "Role of Inflammasome Activation in Atherosclerosis"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Clinical Immunology".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 1742

Special Issue Editors

Division of Dermatology and Venereology, Department of Medicine, University of Verona, Piazzale A. Stefani 1, I-37126 Verona, Italy
Interests: psoriasis; psoriatic arthritis; atopic dermatitis; immunopharmacology; skin biology; skin immune system; skin and internal diseases
Special Issues, Collections and Topics in MDPI journals

Guest Editor Assistant
Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Interests: atherosclerosis; inflammasome; innate immunity; immune treatment; pyroptosis

Special Issue Information

Dear Colleagues,

1) Cardiovascular diseases (CVD) are still the predominant cause of death and morbidity, with atherosclerosis as the main underlying cause. Atherosclerosis is a lipid-driven, chronic inflammatory disease characterized by the build-up of subendothelial deposition of cholesterol and the formation of leukocyte-rich plaques in the intimal layer of the arteries. Innate-immunity-induced inflammation plays a major role in promoting the atherosclerotic plaque, resulting in myocardial infarction and stroke.

Inflammasome biology is one of the most exciting and rapidly growing areas in immunology. Over the past 10 years, inflammasomes have been recognized for their roles in the host defense against invading pathogens and in the development of cancer, metabolic, and neurodegenerative diseases. The assembly of an inflammasome complex requires cytosolic sensing of pathogen-associated molecular patterns or danger-associated molecular patterns by a nucleotidebinding domain and leucine-rich repeat receptor (NLR) or absent in melanoma 2-like receptor (ALR), which further activates caspase-1, cleaves and matures the proinflammatory cytokines. Inflammasome includes NLRP1, NLRP2, NLRP3, AIM2, and NLRC4 have attracted more attention in recent studies.

We are pleased to invite you to help clarify the mechanism of inflammasome in atherosclerosis process, which will facilitate the development of precise therapeutic strategies for CVD.

2) Since inflammasome activation has been shown to be an important mechanism driving atherogenesis, inflammation, and foam cell formation, it could emerge also as a crucial mechanism triggering vascular endothelial cell damage, vascular smooth muscle cells phenotypic switch, and subsequently, plaque destabilization. Until now, this hypothesis has not been investigated, and it could open a door to the revelation of a new mechanism in vascular pathology.

This Special Issue aims to explore and summarize the present knowledge about molecular mechanisms of immune response dysregulation in atherosclerosis induced by inflammasome disorder.

3) Suggested themes and article types for submissions.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following:

  • Construction of early predictive or warning models for inflammasome-related CVD diseases based on inflammation/immune factors;
  • Targeting important immune regulation points in atherosclerosis;
  • Evaluation of anti-inflammation or immune vaccine therapy for the treatment of atherosclerosis-related disease and the atherosclerosis process;
  • Role of inflammasome in regulating phenotypic transformation of vascular smooth muscle cells in atherosclerosis;
  • NLRP3 inflammasome-induced cardiovascular dysfunction;
  • Dysregulation of tone regulation in vascular dysfunction induced by inflammasome;
  • Drug and non-drug treatment towards pyroptosis in CVD.

We look forward to receiving your contributions.

Prof. Dr. Giampiero Girolomoni
Guest Editor

Minghao Luo
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • atherosclerosis
  • inflammasome
  • innate immunity
  • immune treatment
  • pyroptosis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Advances in Molecular Imaging in Infective Endocarditis
Vaccines 2023, 11(2), 420; https://doi.org/10.3390/vaccines11020420 - 12 Feb 2023
Cited by 1 | Viewed by 1459
Infective endocarditis (IE) is a growing epidemiological challenge. Appropriate diagnosis remains difficult due to heterogenous etiopathogenesis and clinical presentation. The disease may be followed by increased mortality and numerous diverse complications. Developing molecular imaging modalities may provide additional insights into ongoing infection and [...] Read more.
Infective endocarditis (IE) is a growing epidemiological challenge. Appropriate diagnosis remains difficult due to heterogenous etiopathogenesis and clinical presentation. The disease may be followed by increased mortality and numerous diverse complications. Developing molecular imaging modalities may provide additional insights into ongoing infection and support an accurate diagnosis. We present the current evidence for the diagnostic performance and indications for utilization in current guidelines of the hybrid modalities: single photon emission tomography with technetium99m-hexamethylpropyleneamine oxime–labeled autologous leukocytes (99mTc-HMPAO-SPECT/CT) along with positron emission tomography with fluorodeoxyglucose (18F-FDG PET/CT). The role of molecular imaging in IE diagnostic work-up has been constantly growing due to technical improvements and the increasing evidence supporting its added diagnostic and prognostic value. The various underlying molecular processes of 99mTc-HMPAO-SPECT/CT as well as 18F-FDG PET/CT translate to different imaging properties, which should be considered in clinical practice. Both techniques provide additional diagnostic value in the assessment of patients at risk of IE. Nuclear imaging should be considered in the IE diagnostic algorithm, not only for the insights gained into ongoing infection at a molecular level, but also for the determination of the optimal clinical therapeutic strategies. Full article
(This article belongs to the Special Issue Role of Inflammasome Activation in Atherosclerosis)
Show Figures

Figure 1

Back to TopTop